Troy Ignelzi
Director/Board Member presso ABIVAX
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Marc M. P. de Garidel | M | 66 | 3 anni | |
| Bernat Olle | M | - |
Vedanta Biosciences, Inc.
 Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 anni |
| June Lee | M | 58 | 1 anni | |
| Philippe Pouletty | M | 65 | 11 anni | |
| Corinna Zur Bonsen-Thomas | M | - | 7 anni | |
| John Tucker | M | 61 | 7 anni | |
| Ben Shapiro | M | 84 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 anni |
| Jack Khattar | M | 62 | 8 anni | |
| Mason W. Freeman | M | 73 | 6 anni | |
| Carol Brosgart | M | 72 | 6 anni | |
| Minnie Baylor-Henry | F | 76 | 6 anni | |
| Pierre Courteille | M | - | - | |
| Klaus Veitinger | M | 62 | 7 anni | |
| James Boland | M | 84 |
Juventas Therapeutics, Inc.
 Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | 9 anni |
| Frederick Hudson | M | 78 | 6 anni | |
| Didier Blondel | M | - | 7 anni | |
| Kenya Honda | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 anni |
| Jeremiah Faith | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| Patrick Malloy | M | - | 1 anni | |
| Regina Jehle | F | - | - | |
| Neil Tiwari | M | 37 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| Hema Keshava | F | - | 3 anni | |
| Sheldon Sloan | M | - | 1 anni | |
| Michael Ferguson | M | - | 1 anni | |
| John Mohr | M | - | 7 anni | |
| Martin Heidecker | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| Daniel Couto | M | 52 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| Susan Dillon | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| Didier Scherrer | M | - | - | |
| Dan Littman | M | 71 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 anni |
| Alexander Rudensky | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 anni |
| Mike Hassman | M | - | 6 anni | |
| Justin Thompson | M | - | 3 anni | |
| Barton Finlay | M | - |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 14 anni |
| Kinam Hong | M | - | - | |
| Curt LaBelle | M | 53 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 1 anni |
| Charles Sherwood | M | 76 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| John LaMattina | M | 74 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | 12 anni |
| Ida Hatoum | F | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Eric Elenko | M | 51 | 10 anni | |
| Atul Pande | M | 69 | 8 anni | |
| James Healy | M | 58 | 5 anni | |
| Jon Isaacsohn | M | - | - | |
| William Meury | M | 56 | 1 anni | |
| Christopher Coughlin | M | 71 | 4 anni | |
| Tim Mayleben | M | 63 | 11 anni | |
| Jonathan Silverstein | M | 57 | 1 anni | |
| Michael Kalb | M | 53 | 1 anni | |
| Martin K. McCarthy | M | 65 |
InSys Therapeutics, Inc. /Old/
 InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 anni |
| Kush Parmar | M | 42 | 4 anni | |
| Rick Bartram | M | 63 | 9 anni | |
| Abhay Gandhi | M | 59 | 2 anni | |
| Denice Torres | F | 64 | 4 anni | |
| Michael L. Babich | M | 47 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 anni |
| David Wheadon | M | 66 | 4 anni | |
| Heather Elizabeth Preston | M | 58 | 2 anni | |
| Patrick Enright | M | 62 | 3 anni | |
| Carol Karp | F | 71 | 1 anni | |
| Edmund Harrigan | M | 71 | 9 anni | |
| Daniel Janney | M | 58 | 9 anni | |
| Mia Kelley | F | - | 4 anni | |
| Jon W. McGarity | M | 82 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 1 anni |
| Jean-Jacques Bertrand | M | 84 | 9 anni | |
| Laurie Olson | F | 61 | 4 anni | |
| Robert Nelsen | M | 60 | 3 anni | |
| Joy Amundson | F | 69 | - | |
| Louis Lange | M | 72 | 4 anni | |
| John Thero | M | 63 | 2 anni | |
| Jason Pitts | M | 38 | 2 anni | |
| Juliana Woda | M | - |
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | 1 anni |
| Mary Coelho | F | 62 | 1 anni | |
| Jonathan Rosin | M | - | 1 anni | |
| Ronald Marcus | M | 65 | 3 anni | |
| Charmaine Lykins | F | 54 | 2 anni | |
| Abraham Ceesay | M | 46 | 2 anni | |
| William Kane | M | 62 | 1 anni | |
| Noah L. Rosenberg | M | 57 | 2 anni | |
| James E. Audia | M | 68 | 5 anni | |
| Ramesh Acharya | M | - |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | - |
| David Allison | M | 42 | 4 anni | |
| Stephen M. Muniz | M | - | - | |
| August Troendle | M | 67 | 3 anni | |
| Maina Bhaman | M | 52 | 4 anni | |
| Joep Muijrers | M | 51 | 1 anni | |
| Steven J. Meyer | M | 67 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 anni |
| Christopher Viehbacher | M | 64 |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | - |
| Jan L. Garfinkle | F | - | 5 anni | |
| Patrick P. Fourteau | M | 77 |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | 4 anni |
| Bharatt Chowrira | M | 59 | 2 anni | |
| Alexis Smith | F | - | 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 76 | 84.44% |
| Francia | 16 | 17.78% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Troy Ignelzi
- Contatti personali
